What’s New in Psoriatic Arthritis Treatment? FDA-Approved Drugs to Know
Treatment options for psoriatic arthritis have expanded well beyond older pain relievers and early biologic drugs. In recent years, the FDA has cleared additional medicines that target specific inflammatory pathways, giving patients and clinicians more ways to balance joint relief, skin control, convenience, and safety. Understanding how these newer choices differ can make treatment discussions more practical and less overwhelming.
Over the past decade, care for psoriatic arthritis has become more targeted. Instead of relying only on broad immune suppression or symptom control, clinicians now have a wider set of FDA-approved medicines aimed at specific inflammatory signals. That matters because psoriatic arthritis does not look the same in every person: some people mainly struggle with swollen joints, others with enthesitis, fatigue, stiffness, nail disease, or significant psoriasis. Newer treatments can help match the drug choice more closely to the pattern of disease.
This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.
New FDA-Approved Drugs to Know
Recent additions and newer classes have expanded the list of options beyond older standards such as methotrexate and tumor necrosis factor, or TNF, inhibitors. FDA-approved drugs to know include IL-17 blockers such as secukinumab and ixekizumab, IL-23 inhibitors such as guselkumab and risankizumab, the oral PDE4 inhibitor apremilast, and targeted oral JAK inhibitors such as upadacitinib and tofacitinib. These medicines are approved for active psoriatic arthritis, although the exact indication and use can differ by product.
What is new is not simply the number of drugs, but the range of treatment approaches. Some medicines are injections taken weekly or monthly, some are given less often after starter doses, and some are tablets. Certain options may be especially useful when skin psoriasis is prominent, while others may be selected when joint inflammation, dactylitis, or enthesitis is the main concern. That broader menu helps doctors individualize treatment rather than follow a one-size-fits-all path.
Newer vs Traditional Treatment Options
When looking at how newer treatments compare with traditional options, the biggest difference is precision. Older treatments such as nonsteroidal anti-inflammatory drugs can reduce pain and stiffness, and conventional disease-modifying drugs such as methotrexate may help some patients, but they do not work equally well for all disease features. Newer biologics and targeted oral medicines are designed to interrupt defined immune pathways, which can improve disease control when traditional steps are not enough or are poorly tolerated.
Real-world cost is also part of the decision. In the United States, newer biologic and targeted oral drugs are often expensive before insurance, frequently costing several thousand dollars per month at list price. Out-of-pocket costs can be much lower with commercial insurance, Medicare coverage, manufacturer support programs, or pharmacy benefit arrangements, but prior authorization and step therapy are common. Biosimilars may improve affordability for some TNF inhibitors, yet overall costs still vary widely by plan, dose, and place of dispensing.
| Product/Service Name | Provider | Key Features | Cost Estimation |
|---|---|---|---|
| Humira | AbbVie | TNF inhibitor; long-established option for joint and skin disease; biosimilar competition exists | High; public U.S. list pricing has historically been in the several-thousand-dollars-per-month range before insurance |
| Cosentyx | Novartis | IL-17A inhibitor; used for joint symptoms and psoriasis; injection schedule varies by phase | High; public U.S. pricing is typically in the high thousands per month before insurance |
| Skyrizi | AbbVie | IL-23 inhibitor; less frequent maintenance dosing after starter phase | High; each dose is costly and annual treatment expense is typically very high without coverage |
| Rinvoq | AbbVie | Oral JAK inhibitor; once-daily tablet; targeted systemic treatment | High; public U.S. pricing is generally several thousand dollars per month before insurance |
| Otezla | Amgen | Oral PDE4 inhibitor; non-biologic option with tablet dosing | High; public U.S. pricing is also commonly several thousand dollars per month before insurance |
Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.
Another practical comparison point is treatment burden. Traditional medicines may require lab monitoring for liver, blood count, or kidney issues, while biologics and JAK inhibitors also come with infection screening and other safety checks. Route matters too: some people prefer an oral drug over injections, while others favor less frequent dosing even if it means using an injectable biologic. The right balance often depends on symptom pattern, convenience, insurance coverage, and past response to therapy.
Side Effects, Safety, and Doctor Talks
Side effects, safety, and what to discuss with your doctor are central when reviewing any newer medicine. Biologics that affect IL-17, IL-23, or TNF pathways can increase infection risk, and injection-site reactions are common. JAK inhibitors carry additional warnings related to serious infections and, in some patients, cardiovascular or clotting concerns. Oral apremilast does not suppress the immune system in the same way as biologics, but gastrointestinal side effects such as nausea or diarrhea can occur, especially early on.
A useful treatment conversation usually includes more than symptom relief alone. Patients and clinicians may review personal infection history, tuberculosis screening, vaccination status, pregnancy planning, inflammatory bowel disease history, liver issues, previous cancer history, and whether skin psoriasis or nail disease needs equal attention. It is also reasonable to ask how quickly a drug may work, what monitoring is required, how success will be measured, and when a change should be considered if improvement is incomplete. With more FDA-approved options available, treatment planning has become more nuanced, but also more flexible and personalized.
